Notícias

Gilead Sciences posts higher revenue as its market-leading HIV drug portfolio continues to drive growth.

The phrase sounds almost impossible: a short squeeze involving index funds. After all, index funds are designed to be passive, rules-based buyers, not active traders caught on the wrong side of a position. Yet that is exactly the scenario Animal Spirits hosts Michael Batnick and Ben Carlson laid out on Episode 467, “The Biggest Short ... SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens.

Gilead Sciences Inc. (NASDAQ:GILD) is one of the cheap NASDAQ stocks to buy right now. On May 21, Gilead Sciences completed the acquisition of Tubulis GmbH, a Germany-based biotechnology company, for $3.15 billion in upfront payments plus up to $1.85 billion in potential milestone considerations. This strategic move bolsters Gilead’s oncology portfolio by integrating Tubulis’ […]

Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.

In early May 2026, Gilead Sciences reported first-quarter 2026 results showing revenue of US$6.96 billion and net income of US$2.02 billion, alongside updated guidance that pairs higher expected product sales with an adjusted full-year earnings loss driven by very large acquisition-related charges. At the same time, Gilead advanced its HIV portfolio with FDA priority review for the once-daily bictegravir/lenacapavir combination and continued returning capital through share repurchases, even...

By Deena Beasley LOS ANGELES, May 7 (Reuters) - Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for